Clinical Research Directory
Browse clinical research sites, groups, and studies.
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Sponsor: Novartis Pharmaceuticals
Summary
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
224
Start Date
2025-05-16
Completion Date
2028-12-22
Last Updated
2025-12-22
Healthy Volunteers
No
Conditions
Interventions
GHZ339
GHZ339 administered at dose A, B, C and D
Placebo
Matching placebo
Locations (99)
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Fort Smith, Arkansas, United States
Novartis Investigative Site
Fountain Valley, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Sacramento, California, United States
Novartis Investigative Site
Santa Ana, California, United States
Novartis Investigative Site
Santa Monica, California, United States
Novartis Investigative Site
Washington D.C., District of Columbia, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Atlanta, Georgia, United States
Novartis Investigative Site
Macon, Georgia, United States
Novartis Investigative Site
Louisville, Kentucky, United States
Novartis Investigative Site
Brighton, Massachusetts, United States
Novartis Investigative Site
Troy, Michigan, United States
Novartis Investigative Site
Saint Joseph, Missouri, United States
Novartis Investigative Site
Brooklyn, New York, United States
Novartis Investigative Site
Arlington, Texas, United States
Novartis Investigative Site
Cypress, Texas, United States
Novartis Investigative Site
Dallas, Texas, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
San Antonio, Texas, United States
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Markham, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Verdun, Quebec, Canada
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Shantou, Guangdong, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Changchun, Jilin, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Plzen Bory, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Lorient, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Reims, France
Novartis Investigative Site
Rouen, France
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Mainz, Rhineland-Palatinate, Germany
Novartis Investigative Site
Bad Bentheim, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Oldenburg, Germany
Novartis Investigative Site
Pécs, Baranya, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Cona, FE, Italy
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Matsudo, Chiba, Japan
Novartis Investigative Site
Kawasaki, Kanagawa, Japan
Novartis Investigative Site
Yokohama, Kanagawa, Japan
Novartis Investigative Site
Habikino, Osaka, Japan
Novartis Investigative Site
Shinagawa Ku, Tokyo, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Kyoto, Japan
Novartis Investigative Site
Rotterdam, South Holland, Netherlands
Novartis Investigative Site
Utrecht, Netherlands
Novartis Investigative Site
Warsaw, Masovian Voivodeship, Poland
Novartis Investigative Site
Katowice, Poland
Novartis Investigative Site
Lodz, Poland
Novartis Investigative Site
Lublin, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Bardejov, Slovakia
Novartis Investigative Site
Komárno, Slovakia
Novartis Investigative Site
Košice, Slovakia
Novartis Investigative Site
Košice, Slovakia
Novartis Investigative Site
Prešov, Slovakia
Novartis Investigative Site
Ansan, Gyeonggi-do, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Badalona, Barcelona, Spain
Novartis Investigative Site
Alicante, Spain
Novartis Investigative Site
Granada, Spain
Novartis Investigative Site
Las Palmas GC, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Pontevedra, Spain
Novartis Investigative Site
Kaohsiung City, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Dudley, West Midlands, United Kingdom
Novartis Investigative Site
Liverpool, United Kingdom